Welcome to our dedicated page for Syneos Health news (Ticker: SYNH), a resource for investors and traders seeking the latest updates and insights on Syneos Health stock.
Syneos Health, Inc. (Nasdaq: SYNH) is a prominent player in the biopharmaceutical solutions industry, offering comprehensive end-to-end clinical and commercial services. With a mission to shorten the distance from lab to life, the company is dedicated to accelerating the success of its clients in the biopharmaceutical sector.
Formed from the merger of INC Research and inVentiv Health, Syneos Health stands out as the only fully integrated biopharmaceutical solutions organization. The company leverages its extensive expertise and data insights to navigate the complexities of today's marketplace, providing smarter and faster solutions to its clients. Its services range from clinical trials to commercialization, ensuring that therapies reach patients efficiently.
Headquartered in Morrisville, N.C., Syneos Health operates in more than 110 countries, employing a talented team of professionals who deeply understand patient and physician behaviors as well as market dynamics. The company is committed to fostering a diverse, equitable, and inclusive culture, focusing on the well-being of its colleagues, customers, patients, communities, and the environment.
One of Syneos Health's recent significant achievements includes an agreement to go private through an acquisition by a consortium of private investment firms, which includes Elliott Investment Management L.P., Patient Square Capital, and Veritas Capital. This transaction, approved by the company's stockholders, is expected to bolster Syneos Health's growth priorities and enhance its ability to deliver integrated solutions to its clients.
Among its current projects, Syneos Health has been enhancing its patient recruitment capabilities through a collaboration with Oracle Cerner LHN to address unmet needs in clinical trial enrollment and diversity. Furthermore, the company continues to invest in technology and data solutions to optimize clinical development and performance for its customers.
Financially, Syneos Health operates on solid footing, with ongoing support from its new private investors poised to further accelerate its transformation and fuel investments in technology. The company's commitment to innovation and customer success positions it as a leading force in the biopharmaceutical industry.
To stay updated on Syneos Health's latest developments, including their quarterly reports and strategic initiatives, visit syneoshealth.com and subscribe to their podcast.
Syneos Health (Nasdaq:SYNH) has appointed Michael Brooks as Chief Development Officer, signaling its commitment to growth and innovation in biopharmaceutical product development. Brooks, with over 25 years of experience, will lead the company’s Customer Engagement and Market Development initiatives to enhance patient outcomes. CEO Alistair Macdonald emphasized the need for exceptional customer experiences post-COVID-19. Brooks previously held leadership roles at LabCorp and PRA Health Sciences, where he focused on global clinical development and commercialization.
Syneos Health (Nasdaq:SYNH) will release its second quarter 2021 financial results on August 9, 2021, before the earnings call at 8:00 a.m. ET. The earnings call will be accessible via a live webcast on the company's Investor Relations website. Participants can register in advance to join the call by phone, receiving a confirmation email with details on how to connect. A replay of the webcast will be available after 1:00 p.m. on the same day. This event marks an important opportunity for investors to gather insights on the company's performance.
Syneos Health (Nasdaq:SYNH) has launched a Decentralized Clinical Trials Site Advocacy Group to enhance its Decentralized Solutions, following the recent acquisition of Illingworth Research Group. This initiative seeks to engage with stakeholders and leverage insights to improve decentralized protocol design and patient engagement in clinical trials. The Group aims to streamline operations and reduce patient burdens by incorporating innovative technologies like mobile research and telemedicine. The move is part of Syneos Health's ongoing commitment to accelerate therapy delivery.
Syneos Health (Nasdaq:SYNH) announced the appointment of Dr. David S. Wilkes to its Board of Directors, enhancing leadership with his extensive expertise in pulmonary disease and critical care medicine. Dr. Wilkes, Dean at the University of Virginia School of Medicine, brings a robust academic and entrepreneurial background. The announcement follows the resignation of John Maldonado and Josh Nelson from the Board, which now consists of 10 directors, nine being independent. This transition is aimed at strengthening the Board's composition to better impact patient lives and address healthcare disparities.
Syneos Health (Nasdaq:SYNH) has launched the Patient Voice Consortium, a cross-functional hub aimed at integrating patient perspectives into the product lifecycle. This initiative responds to increased recognition of the 'patient voice' in product development, driven by advocacy and regulatory efforts like the FDA's Patient-Focused Drug Development initiative. The Consortium combines expertise in various fields, including behavioral science and health policy, to enhance patient outcomes and address disparities in healthcare access. This initiative is part of Syneos Health's commitment to innovation and diversity.
Syneos Health, Inc. (Nasdaq: SYNH) announced the pricing of a secondary offering by affiliates of Thomas H. Lee Partners and Advent International of 10,851,676 shares of common stock. Syneos is not selling any shares and will not receive proceeds from the offering, which closes on June 7, 2021. Additionally, the company will repurchase 500,000 shares at the offering price from the selling stockholders, subject to customary conditions. BofA Securities acts as the sole underwriter. This offering is part of Syneos' ongoing capital management strategy.
Syneos Health (Nasdaq: SYNH) has announced a secondary offering of 10,851,676 shares initiated by affiliates of Thomas H. Lee Partners and Advent International. The company is not selling any shares and will not receive proceeds from this transaction. Concurrently, Syneos Health will repurchase 500,000 shares from the Selling Stockholders at the offering price minus commissions.
BofA Securities is the sole underwriter for this offering, which is set to be executed under a previously filed SEC registration statement.
Syneos Health (Nasdaq: SYNH) announced the pricing of an underwritten secondary offering by affiliates of Thomas H. Lee Partners and Advent International. A total of 7,000,000 shares of common stock are being offered, with an additional 1,050,000 shares available to the underwriter. The offering closes on May 6, 2021. Syneos Health is not selling shares and will not receive proceeds from the offering. Additionally, the company will repurchase 400,000 shares from the selling stockholders at the offering price, contingent on the offering's closing.
Syneos Health (Nasdaq: SYNH) announced a secondary offering of 7,000,000 shares by affiliates of Thomas H. Lee Partners and Advent International. The underwriter, B of A Securities, has an option to purchase an additional 1,050,000 shares. Syneos will repurchase 400,000 shares from the Selling Stockholders at the offering price. The offering proceeds will not benefit Syneos, as they are only selling shares held by stockholders. The share repurchase is contingent upon the offering’s closing. Important risks include reliance on key personnel and potential market fluctuations.
FAQ
What is the market cap of Syneos Health (SYNH)?
What is Syneos Health, Inc.?
What recent achievement did Syneos Health announce?
What services does Syneos Health offer?
What is the significance of Syneos Health's collaboration with Oracle Cerner LHN?
How many countries does Syneos Health operate in?
What is Syneos Health's commitment to diversity and inclusion?
What is Syneos Health's financial condition?
Where can I find more information about Syneos Health's latest developments?
What is the main goal of Syneos Health?
Who are the private investment firms involved in the acquisition of Syneos Health?
